- Home
- KMPR vs MLYS Comparison
KMPR vs MLYS Comparison
Compare KMPR & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMPR
- MLYS
- Stock Information
- Founded
- KMPR 1990
- MLYS 2019
- Country
- KMPR United States
- MLYS United States
- Employees
- KMPR N/A
- MLYS N/A
- Industry
- KMPR Property-Casualty Insurers
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- KMPR Finance
- MLYS Health Care
- Exchange
- KMPR Nasdaq
- MLYS Nasdaq
- Market Cap
- KMPR 3.3B
- MLYS 3.1B
- IPO Year
- KMPR N/A
- MLYS 2023
- Fundamental
- Price
- KMPR $47.35
- MLYS $42.64
- Analyst Decision
- KMPR Buy
- MLYS Strong Buy
- Analyst Count
- KMPR 4
- MLYS 6
- Target Price
- KMPR $67.50
- MLYS $42.60
- AVG Volume (30 Days)
- KMPR 1.1M
- MLYS 1.4M
- Earning Date
- KMPR 11-05-2025
- MLYS 11-10-2025
- Dividend Yield
- KMPR 2.76%
- MLYS N/A
- EPS Growth
- KMPR 562.92
- MLYS N/A
- EPS
- KMPR 5.31
- MLYS N/A
- Revenue
- KMPR $4,784,500,000.00
- MLYS N/A
- Revenue This Year
- KMPR $0.77
- MLYS N/A
- Revenue Next Year
- KMPR $6.74
- MLYS N/A
- P/E Ratio
- KMPR $8.74
- MLYS N/A
- Revenue Growth
- KMPR 2.67
- MLYS N/A
- 52 Week Low
- KMPR $45.02
- MLYS $8.24
- 52 Week High
- KMPR $73.01
- MLYS $44.32
- Technical
- Relative Strength Index (RSI)
- KMPR 33.90
- MLYS 68.44
- Support Level
- KMPR $45.55
- MLYS $37.54
- Resistance Level
- KMPR $50.52
- MLYS $43.88
- Average True Range (ATR)
- KMPR 1.19
- MLYS 2.36
- MACD
- KMPR -0.21
- MLYS -0.36
- Stochastic Oscillator
- KMPR 23.97
- MLYS 73.48
About KMPR Kemper Corporation
Kemper Corp is a diversified insurance company that provides services in property and casualty insurance, along with life and health insurance. The company's property and casualty segment offers personal and commercial lines for home and automotive products. The company conducts its operations through two operating segments: Specialty Property & Casualty Insurance, and Life Insurance.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.